Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2021.792453 Oncology Correction Corrigendum: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer DuanTinghui 1 † ZhouDiyuan 2 † YaoYizhou 2 * ShaoXinyu 3 * 1Department of Medical Imaging, The Affiliated Guangji Hospital of Soochow University, Suzhou, China 2Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China 3Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China

Edited and reviewed by: Alessandro Passardi, Romagnolo Scientific Institute for the Study and Treatment of Tumors (IRCCS), Italy

†These authors have contributed equally to this work

*Correspondence: Xinyu Shao, xinxinyuxin0711@163.com; Yizhou Yao, yzyao@suda.edu.cn

This article was submitted to Gastrointestinal Cancers: Colorectal Cancer, a section of the journal Frontiers in Oncology

 25 10 2021 2021 11 792453 10 10 2021 11 10 2021 Copyright © 2021 Duan, Zhou, Yao and Shao 2021 Duan, Zhou, Yao and Shao

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer by Duan T, Zhou D, Yao Y and Shao X (2021) Front. Oncol. 11:706838. doi: 10.3389/fonc.2021.706838 colorectal cancer FGF1 mTOR-S6K1 pathway prognosis survival

In the original article, there was a mistake in Figure 7B as published. We identified a minor error in image-misusing was made. The corrected Figure 7 appears below.

FGF1 promotes proliferation and migration ability of CRC cells. (A, B) Colony formation capacity (A) and migration rates (B) of FGF1-KD CRC cells. CRC, colorectal cancer. (C) Wound healing assays were carried out at 24h after transfection in 6-well plates. The gap width was measured using Open Lab software. (D) The wound rate was calculated and displayed graphically according to the measured results by Open Lab software. NC, negative control; KD, FGF1-shRNA. Data are presented as mean ± SD (n=3). Ns, no significance, *P < 0.05.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.